CL2018003443A1 - Tratamientos para el cancer. - Google Patents
Tratamientos para el cancer.Info
- Publication number
- CL2018003443A1 CL2018003443A1 CL2018003443A CL2018003443A CL2018003443A1 CL 2018003443 A1 CL2018003443 A1 CL 2018003443A1 CL 2018003443 A CL2018003443 A CL 2018003443A CL 2018003443 A CL2018003443 A CL 2018003443A CL 2018003443 A1 CL2018003443 A1 CL 2018003443A1
- Authority
- CL
- Chile
- Prior art keywords
- treatments
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609600.0A GB201609600D0 (en) | 2016-06-01 | 2016-06-01 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003443A1 true CL2018003443A1 (es) | 2019-08-09 |
Family
ID=56410849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003443A CL2018003443A1 (es) | 2016-06-01 | 2018-11-30 | Tratamientos para el cancer. |
| CL2021002669A CL2021002669A1 (es) | 2016-06-01 | 2021-10-12 | (divisional de solicitud 3443-2018) tratamientos de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002669A CL2021002669A1 (es) | 2016-06-01 | 2021-10-12 | (divisional de solicitud 3443-2018) tratamientos de cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11400107B2 (OSRAM) |
| EP (1) | EP3463384A1 (OSRAM) |
| JP (2) | JP7367910B2 (OSRAM) |
| KR (2) | KR20190011770A (OSRAM) |
| CN (1) | CN109562119A (OSRAM) |
| AU (1) | AU2017273124B2 (OSRAM) |
| BR (1) | BR112018074981A2 (OSRAM) |
| CA (1) | CA3025442C (OSRAM) |
| CL (2) | CL2018003443A1 (OSRAM) |
| EA (1) | EA038030B1 (OSRAM) |
| GB (1) | GB201609600D0 (OSRAM) |
| IL (1) | IL263123B (OSRAM) |
| MA (1) | MA45129A (OSRAM) |
| MX (1) | MX2018014840A (OSRAM) |
| MY (1) | MY199129A (OSRAM) |
| PH (1) | PH12018502491A1 (OSRAM) |
| SG (1) | SG11201810196RA (OSRAM) |
| WO (1) | WO2017207993A1 (OSRAM) |
| ZA (1) | ZA201807811B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2828326C (en) | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| MX394059B (es) | 2014-11-28 | 2025-03-24 | NuCana plc | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| EP3866932A4 (en) * | 2018-10-17 | 2022-11-30 | Xibin Liao | 6-mercaptopurine nucleoside analogues |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| CA3171648A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| PL4323362T3 (pl) | 2021-04-16 | 2025-08-18 | Gilead Sciences, Inc. | Sposoby wytwarzania karbanukleozydów z zastosowaniem amidów |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
| HRP20160949T1 (hr) | 2007-09-10 | 2016-10-07 | Boston Biomedical, Inc. | Novi sastavi i metode za liječenje karcinoma |
| CA2723648A1 (en) | 2008-04-10 | 2009-10-15 | Piyush Gupta | Methods for identification and use of agents targeting cancer stem cells |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CA2828326C (en) * | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| WO2015181624A2 (en) | 2014-05-28 | 2015-12-03 | Idenix Pharmaceuticals, Inc | Nucleoside derivatives for the treatment of cancer |
| HRP20201264T1 (hr) * | 2014-06-25 | 2021-02-05 | NuCana plc | Prolijekovi gemcitabina |
| LT3119794T (lt) * | 2014-06-25 | 2018-02-12 | NuCana plc | Kompozicija, apimanti gemcitabino provaistą |
| MX394059B (es) * | 2014-11-28 | 2025-03-24 | NuCana plc | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer |
| CA2985540C (en) * | 2015-05-14 | 2021-08-24 | NuCana plc | Use of nuc-1031 in the treatment of cancer |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
-
2016
- 2016-06-01 GB GBGB1609600.0A patent/GB201609600D0/en not_active Ceased
-
2017
- 2017-05-31 IL IL263123A patent/IL263123B/en unknown
- 2017-05-31 CN CN201780048221.8A patent/CN109562119A/zh active Pending
- 2017-05-31 US US16/305,162 patent/US11400107B2/en active Active
- 2017-05-31 EA EA201892803A patent/EA038030B1/ru unknown
- 2017-05-31 SG SG11201810196RA patent/SG11201810196RA/en unknown
- 2017-05-31 CA CA3025442A patent/CA3025442C/en active Active
- 2017-05-31 KR KR1020187037533A patent/KR20190011770A/ko not_active Ceased
- 2017-05-31 JP JP2018563084A patent/JP7367910B2/ja active Active
- 2017-05-31 MY MYPI2018002142A patent/MY199129A/en unknown
- 2017-05-31 AU AU2017273124A patent/AU2017273124B2/en active Active
- 2017-05-31 BR BR112018074981-8A patent/BR112018074981A2/pt not_active Application Discontinuation
- 2017-05-31 EP EP17728604.4A patent/EP3463384A1/en active Pending
- 2017-05-31 KR KR1020227034733A patent/KR20220142538A/ko not_active Ceased
- 2017-05-31 WO PCT/GB2017/051560 patent/WO2017207993A1/en not_active Ceased
- 2017-05-31 MA MA045129A patent/MA45129A/fr unknown
- 2017-05-31 MX MX2018014840A patent/MX2018014840A/es unknown
-
2018
- 2018-11-20 ZA ZA2018/07811A patent/ZA201807811B/en unknown
- 2018-11-26 PH PH12018502491A patent/PH12018502491A1/en unknown
- 2018-11-30 CL CL2018003443A patent/CL2018003443A1/es unknown
-
2021
- 2021-10-12 CL CL2021002669A patent/CL2021002669A1/es unknown
-
2022
- 2022-02-15 JP JP2022020897A patent/JP2022051965A/ja active Pending
- 2022-08-01 US US17/878,747 patent/US20230218655A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA45129A (fr) | 2021-05-05 |
| US20230218655A1 (en) | 2023-07-13 |
| KR20190011770A (ko) | 2019-02-07 |
| CN109562119A (zh) | 2019-04-02 |
| IL263123B (en) | 2022-09-01 |
| AU2017273124A1 (en) | 2018-12-13 |
| SG11201810196RA (en) | 2018-12-28 |
| JP2022051965A (ja) | 2022-04-01 |
| MX2018014840A (es) | 2019-03-14 |
| US11400107B2 (en) | 2022-08-02 |
| IL263123A (en) | 2018-12-31 |
| CA3025442A1 (en) | 2017-12-07 |
| BR112018074981A2 (pt) | 2019-03-12 |
| JP2019521971A (ja) | 2019-08-08 |
| KR20220142538A (ko) | 2022-10-21 |
| ZA201807811B (en) | 2024-05-30 |
| CA3025442C (en) | 2024-02-20 |
| MY199129A (en) | 2023-10-17 |
| PH12018502491A1 (en) | 2019-09-09 |
| JP7367910B2 (ja) | 2023-10-24 |
| CL2021002669A1 (es) | 2022-05-27 |
| WO2017207993A1 (en) | 2017-12-07 |
| AU2017273124B2 (en) | 2022-09-29 |
| EA038030B1 (ru) | 2021-06-25 |
| EA201892803A1 (ru) | 2019-06-28 |
| US20190374564A1 (en) | 2019-12-12 |
| GB201609600D0 (en) | 2016-07-13 |
| EP3463384A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003443A1 (es) | Tratamientos para el cancer. | |
| IL255217A0 (en) | Cancer neoepitopes | |
| PT3283527T (pt) | Terapêutica de combinação para o cancro | |
| IL247001A0 (en) | Treatments for resistant acne | |
| BR112017023853A2 (pt) | composições de nanopartícula para terapia sustentada. | |
| CL2014003041S1 (es) | Carcasa para aoutoinyector. | |
| EP3474854A4 (en) | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER | |
| PL3458052T3 (pl) | Leczenie skojarzone nowotworu | |
| IL268463A (en) | Cancer treatment | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| CL2015002084S1 (es) | Accesorio para calzado. | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| HUE040167T2 (hu) | Rákkezelés | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| LT3265565T (lt) | Vėžio, turinčio hemizigotinį praradimą, gydymo būdai | |
| BR112016029236A2 (pt) | métodos para tratar prurido. | |
| IT201600084952A1 (it) | Coglifrutta. | |
| LT3383385T (lt) | Melflufeno dozavimo režimas vėžio atveju | |
| PT3405212T (pt) | Vacinas para o cancro | |
| DK3407909T5 (da) | Cancerbehandling | |
| MA42609A (fr) | Polythérapie contre le cancer | |
| EP3576534A4 (en) | CANCER TREATMENT | |
| CL2017002884A1 (es) | Tratamientos para el cancer | |
| ES1158435Y (es) | Ascensor para espacios reducidos. |